Metformin Vicious Cycle

Skeletal muscle is responsible for clearing about 80% of the glucose that enters your bloodstream after a meal, and that single fact changes how you have to think about blood sugar management, insulin resistance, and the drugs used to treat them.

When you eat, your blood glucose rises, insulin gets released, and that insulin signals your cells to pull glucose in and use it. Most people assume this is happening evenly across the body, a little in the liver, a little in fat cells, a little everywhere. But the research from DeFronzo and colleagues going back to 1981 showed that skeletal muscle alone accounts for roughly 80% of that glucose disposal. The liver handles some. Fat tissue handles a small amount. But muscle is doing the majority of the work.

So if you do not have enough muscle, you have lost the primary system responsible for keeping your blood sugar in a normal range. And that is not a side effect of insulin resistance, it is one of the mechanisms driving it. Less muscle means less tissue available to absorb glucose, which means blood sugar stays elevated, which means insulin has to keep getting released, which means your cells start down-regulating their sensitivity to it. The whole cascade starts with a tissue deficit.

That is the map. Now here is where metformin fits into it.

Metformin works by inhibiting something called Complex I, which is the first step in the electron transport chain inside your mitochondria, the process your cells use to convert fuel into usable energy. When Complex I gets partially inhibited, the ratio of AMP to ATP inside the cell shifts, and that activates an enzyme called AMPK, which stands for AMP-activated protein kinase. You can think of AMPK as a cellular fuel gauge. When energy is low, AMPK turns on to conserve resources and find alternative ways to bring energy back up. One of the things it does in that mode is increase glucose uptake into muscle cells through a mechanism that does not require insulin. That is the mechanism behind the drug's effect on blood sugar, and it works.

But AMPK does something else too. It suppresses a pathway called mTOR, specifically mTORC1, which is the primary signal your body uses to build new muscle protein after training. AMPK does this through two separate routes: it phosphorylates a protein called TSC2 that acts as a brake on mTOR, and it directly phosphorylates a component of mTORC1 called Raptor. Both actions lead to the same outcome, which is that the signal to build new muscle tissue gets turned down. When AMPK is chronically elevated, the anabolic signal that should follow a resistance training session is blunted at the level of the pathway, not just slightly reduced.

This is not theoretical. The MASTERS trial took 94 adults over the age of 65 and assigned them to either metformin or placebo during 14 weeks of progressive resistance training. The researchers expected metformin to enhance the results because of its known anti-inflammatory properties, and inflammation does impair muscle protein synthesis, so the hypothesis was reasonable. But the placebo group gained significantly more muscle mass and more muscle density than the metformin group. The drug that was supposed to help with metabolic health was actively interfering with the training adaptation that most improves it.

A separate study by Konopka and colleagues looked specifically at the mitochondrial response to exercise in older adults taking metformin versus placebo. Exercise training is supposed to increase mitochondrial capacity in muscle, more mitochondria, better function, greater ability to oxidize glucose and fat. That adaptation is part of why trained muscle is better at clearing blood sugar than untrained muscle. The metformin group showed blunted mitochondrial adaptations compared to placebo, meaning the drug that partially works by affecting mitochondria was also interfering with the mitochondrial improvements that exercise is supposed to produce.

Now here is where the cycle becomes visible. You arrive at a doctor's office with elevated blood sugar. You likely have reduced muscle mass, because muscle loss and insulin resistance tend to develop together over time. You get prescribed metformin, which helps manage blood sugar in the short term through the AMPK mechanism. You may also be advised to exercise. But if you are taking metformin, the AMPK suppression of mTOR means you are building less muscle from that training than you would otherwise, and you are getting fewer mitochondrial adaptations from the aerobic component. So the tissue deficit that contributed to your insulin resistance in the first place does not fully resolve, your blood sugar stays difficult to manage without medication, and the prescription continues.

The drug is doing something real and the blood sugar management is not imaginary. For people with type 2 diabetes, metformin has decades of safety data and meaningful outcomes on long-term complications. That context matters and this is not an argument to stop taking a prescribed medication.

But the mechanism creates a conflict that is worth understanding. If the goal is to rebuild the tissue that clears blood sugar, and that tissue is built through a pathway that metformin partially suppresses, then relying on the drug without addressing the underlying muscle deficit means you are managing a symptom while the condition that produces it remains in place.

Resistance training is the intervention that directly targets the root problem, building the tissue that does 80% of the work. If you are on metformin and training, you may need to have an explicit conversation with your doctor about what the goals are, because optimizing for drug-managed blood sugar and optimizing for building the muscle that would make the drug less necessary are not always the same strategy.

The body can clear blood sugar without medication. It just needs enough muscle to do it.

---

References

1. DeFronzo RA et al. (1981). "The effect of insulin on the disposal of intravenous glucose." J Clin Invest. 68(6):1468-1474. Finding: Skeletal muscle responsible for approximately 80% of insulin-mediated glucose disposal. PMID: 7033285
2. DeFronzo RA (2009). "From the triumvirate to the ominous octet." Banting Lecture. Diabetes Care. 32(Suppl 2):S157-S163. Finding: Muscle insulin resistance is a core defect in type 2 diabetes. PMID: 19875544
3. Walton RG et al. (2019). "Metformin blunts muscle hypertrophy in response to progressive resistance exercise training in older adults: The MASTERS trial." Aging Cell. 18(6):e13039. Finding: n=94, adults 65+, placebo group gained significantly more muscle. PMID: 31557380
4. Konopka AR et al. (2019). "Metformin inhibits mitochondrial adaptations to aerobic exercise training in older adults." Aging Cell. 18(1):e12880. Finding: Metformin blocked exercise-induced mitochondrial improvements. PMID: 30548390
5. Drewe J et al. (2026). "Metformin: Mechanism of action." Pharmacol Rev. Finding: Complex I inhibition activates AMPK. PMID: 41389439
6. Inoki K et al. (2003). Nat Cell Biol. Finding: AMPK phosphorylates TSC2, suppressing mTOR. PMID: 12847286
7. Gwinn DM et al. (2008). Mol Cell. Finding: AMPK phosphorylates Raptor to suppress mTORC1. PMID: 18439900
8. Bolster DR et al. (2002). J Biol Chem. Finding: AMPK activation reduces muscle protein synthesis through mTOR suppression. PMID: 12351658

---

Join the free community:
Men: Iron Forge Brotherhood
Women: Powerhouse Fitness